semaglutide mash GLP-1 BREAKTHROUGH: FDA APPROVES TREATMENT FOR SERIOUS LIVER DISEASE Semaglutide, a medication already known for its role in weight management, is now the first GLP-1 therapy approved to treat (Metabolic Dysfunction–Associated Semaglutide targets MASH molecular pathways

Wium-Andersen IK, Osler M, Jrgensen MB, Rungby J, Wium-Andersen MK

The pharmacokinetic profile of semaglutide means your body gradually accumulates the drug with each weekly dose until it reaches equilibrium

Mol Cell (2013) 49(5):82537.10.1016/j.molcel.2013.01.038 86 HeintzmanNDStuartRKHonGFuYChingCWHawkinsRDet alDistinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome

But we dont just want to lose weight, we want to lose body fat

Characteristic symptoms include sudden-onset pain in the right upper quadrant or epigastrium, pain radiating to the right shoulder, episodes lasting 30 minutes to several hours (often after fatty meals), and associated nausea and vomiting